GRAIL, Inc. is a biotechnology company focused on the early detection of cancer through innovative blood tests. The company is dedicated to advancing its proprietary multi-cancer early detection technology, which aims to identify various types of cancer in their earliest, most treatable stages. By utilizing advanced genomic science and machine learning techniques, GRAIL seeks to improve patient outcomes and transform the landscape of cancer diagnostics, ultimately contributing to earlier interventions and better survival rates. Read More
Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Grail, Inc. (NASDAQ: GRAL). The investigation focuses on Grail’s executive officers and whether investor losses may be recovered under federal securities laws.
In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an ambitious price target of $105.00. The move comes as the liquid biopsy pioneer reported preliminary full-year 2025 financial
GRAIL (GRAL) Q3 2025 earnings beat estimates on revenue and EPS, sending the stock higher. Strong growth for its Galleri cancer test drove the positive results.
